Revolution Medicines’ daraxonrasib won a major Phase 3 survival signal in metastatic pancreatic cancer, driving deal and pipeline attention around its RAS-targeting approach. The company reported median overall survival of 13.2 months versus 6.7 months for chemotherapy and said it will use the data to pursue FDA approval. The dataset, framed around RAS “ON-state” targeting, spans patients with and without an identified RAS mutation, with endpoints emphasizing progression-free survival and overall survival. Revolution positioned the study as a potential shift away from cytotoxic chemotherapy in one of the most treatment-resistant RAS-driven cancers. Separately, a follow-up analysis noted how market expectations around potential buyouts and regulatory filings have escalated since the Phase 3 readout.